Low dose inocula of SARS-CoV-2 B.1.1.7 variant initiate more robust infections in the upper respiratory tract of hamsters than earlier D614G variants
Mok, B. W.-Y.; Liu, H.; Lau, S.-Y.; Deng, S. D.; Liu, S.; Tam, R. C.-Y.; Ng, T. T.-L.; Leung, J. S.-L.; Wang, P.; To, K. K.-W.; Chan, J. F.-W.; Chan, K.-H.; Yuen, K.-Y.; Siu, G. K.-H.; Chen, H.
Show abstract
There is a lack of experimental evidence to explain how the B.1.1.7 variant spreads more quickly than pre-existing variants in humans. We found that B.1.1.7 displays increased competitive fitness over earlier D614G lineages in an in-vitro system. Furthermore,, we demonstrated that B.1.1.7 variant is able to replicate and shed more efficiently in the nasal cavity than other variants with lower dose and shorter duration of exposure.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines 97%
- The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity 97%
- The spike gene is a major determinant for the SARS-CoV-2 Omicron-BA.1 phenotype 96%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.